Foster & Motley Inc. Boosts Holdings in Bristol-Myers Squibb (NYSE:BMY)

Foster & Motley Inc. raised its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 25.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,842 shares of the biopharmaceutical company's stock after purchasing an additional 6,684 shares during the quarter. Foster & Motley Inc.'s holdings in Bristol-Myers Squibb were worth $1,858,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BMY. Reston Wealth Management LLC purchased a new position in shares of Bristol-Myers Squibb in the 3rd quarter valued at $25,000. Hollencrest Capital Management grew its stake in Bristol-Myers Squibb by 61.3% during the 3rd quarter. Hollencrest Capital Management now owns 492 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 187 shares during the last quarter. Kennebec Savings Bank acquired a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $28,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol-Myers Squibb in the 3rd quarter valued at $29,000. Finally, Valued Wealth Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 1,168.1% in the third quarter. Valued Wealth Advisors LLC now owns 596 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 549 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BMY has been the topic of several recent research reports. BMO Capital Markets upped their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a "market perform" rating in a report on Tuesday, November 12th. Bank of America restated a "neutral" rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, December 10th. UBS Group lifted their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a "neutral" rating in a research report on Wednesday, October 9th. Citigroup upped their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock a "neutral" rating in a research report on Tuesday. Finally, Daiwa America raised shares of Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $56.60.

Bristol-Myers Squibb Trading Up 0.8 %

NYSE:BMY traded up $0.46 on Friday, reaching $59.60. 589,873 shares of the company's stock were exchanged, compared to its average volume of 9,187,332. The business has a fifty day moving average of $57.60 and a 200-day moving average of $53.06. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.10. The firm has a market capitalization of $120.88 billion, a price-to-earnings ratio of -16.61, a price-to-earnings-growth ratio of 2.10 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.49 by $0.31. The firm had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm's revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.00 EPS. As a group, analysts expect that Bristol-Myers Squibb will post 0.92 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be paid a $0.62 dividend. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.16%. The ex-dividend date is Friday, January 3rd. Bristol-Myers Squibb's dividend payout ratio (DPR) is presently -69.08%.

Insider Buying and Selling

In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares of the company's stock, valued at approximately $654,091.20. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.09% of the stock is currently owned by insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.